Anika Therapeutics, Inc. Payments to Acquire Marketable Securities
Anika Therapeutics, Inc. (ANIK) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2023-03-16
- Anika Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2021-12-31 was $0.00.
- Anika Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2021-09-30 was $0.00.
- Anika Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $0.00.
- Anika Therapeutics, Inc. payments to acquire marketable securities for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Anika Therapeutics, Inc. payments to acquire marketable securities for fiscal 2020 was $20.04K, a 99.98% decline from fiscal 2019.
- Anika Therapeutics, Inc. payments to acquire marketable securities for fiscal 2019 was $103.85M, a 13.37% increase from fiscal 2018.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | -$20.01M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | -$20.01M derived: sum of 3 quarters · filed 2023-03-16 | -$20.01M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | -$20.01M derived: sum of 2 quarters · filed 2023-03-16 | -$20.01M derived: sum of 3 quarters · filed 2023-03-16 | -$13.77M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2020-12-31 | -$20.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$20.01M derived: sum of 2 quarters · filed 2023-03-16 | -$13.77M derived: sum of 3 quarters · filed 2023-03-16 | $20.04K 10-K · filed 2023-03-16 | $20.04M 10-K · filed 2021-03-05 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $6.25M derived: sum of 2 quarters · filed 2021-11-05 | $20.04M 10-Q · filed 2021-11-05 | $37.52M derived: sum of 4 quarters · filed 2022-03-11 | |||
| 2020-06-30 | $6.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $20.04M 10-Q · filed 2021-08-06 | $37.52M derived: sum of 3 quarters · filed 2022-03-11 | $49.99M derived: sum of 4 quarters · filed 2022-03-11 | |||
| 2020-03-31 | $13.79M 10-Q · filed 2021-05-07 | $31.27M derived: sum of 2 quarters · filed 2022-03-11 | $43.74M derived: sum of 3 quarters · filed 2022-03-11 | $58.65M derived: sum of 4 quarters · filed 2022-03-11 | |||
| 2019-12-31 | $17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $29.95M derived: sum of 2 quarters · filed 2022-03-11 | $44.87M derived: sum of 3 quarters · filed 2022-03-11 | $103.85M 10-K · filed 2022-03-11 | |||
| 2019-09-30 | $12.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $27.39M derived: sum of 2 quarters · filed 2020-11-05 | $86.37M 10-Q · filed 2020-11-05 | $100.29M derived: sum of 4 quarters · filed 2021-04-26 | |||
| 2019-06-30 | $14.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $73.90M 10-Q · filed 2020-08-07 | $87.81M derived: sum of 3 quarters · filed 2021-04-26 | $151.50M derived: sum of 4 quarters · filed 2021-04-26 | |||
| 2019-03-31 | $58.98M 10-Q · filed 2020-05-22 | $72.90M derived: sum of 2 quarters · filed 2021-04-26 | $136.58M derived: sum of 3 quarters · filed 2021-04-26 | $138.08M derived: sum of 4 quarters · filed 2021-04-26 | |||
| 2018-12-31 | $13.92M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-26 | $77.60M derived: sum of 2 quarters · filed 2021-04-26 | $79.10M derived: sum of 3 quarters · filed 2021-04-26 | $91.60M 10-K/A · filed 2021-04-26 | |||
| 2018-09-30 | $63.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $65.18M derived: sum of 2 quarters · filed 2019-10-28 | $77.68M 10-Q · filed 2019-10-28 | $86.18M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2018-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-26 | $14.00M 10-Q · filed 2019-07-26 | $22.50M derived: sum of 3 quarters · filed 2020-03-06 | $34.50M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2018-03-31 | $12.50M 10-Q · filed 2019-05-06 | $21.00M derived: sum of 2 quarters · filed 2020-03-06 | $33.00M derived: sum of 3 quarters · filed 2020-03-06 | $46.25M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2017-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $20.50M derived: sum of 2 quarters · filed 2020-03-06 | $33.75M derived: sum of 3 quarters · filed 2020-03-06 | $45.00M 10-K · filed 2020-03-06 | |||
| 2017-09-30 | $12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $25.25M derived: sum of 2 quarters · filed 2018-10-26 | $36.50M 10-Q · filed 2018-10-26 | $43.50M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-06-30 | $13.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $24.50M 10-Q · filed 2018-07-31 | $31.50M derived: sum of 3 quarters · filed 2019-02-27 | $41.25M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-03-31 | $11.25M 10-Q · filed 2018-05-10 | $18.25M derived: sum of 2 quarters · filed 2019-02-27 | $28.00M derived: sum of 3 quarters · filed 2019-02-27 | $41.00M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $16.75M derived: sum of 2 quarters · filed 2019-02-27 | $29.75M derived: sum of 3 quarters · filed 2019-02-27 | $39.25M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $9.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $22.75M derived: sum of 2 quarters · filed 2017-10-27 | $32.25M 10-Q · filed 2017-10-27 | $47.49M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $22.50M 10-Q · filed 2017-07-28 | $37.74M derived: sum of 3 quarters · filed 2018-02-27 | $45.73M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $9.50M 10-Q · filed 2017-05-04 | $24.74M derived: sum of 2 quarters · filed 2018-02-27 | $32.73M derived: sum of 3 quarters · filed 2018-02-27 | $47.50M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $23.23M derived: sum of 2 quarters · filed 2018-02-27 | $38.00M derived: sum of 3 quarters · filed 2018-02-27 | $45.25M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $7.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $22.76M derived: sum of 2 quarters · filed 2016-11-01 | $30.01M 10-Q · filed 2016-11-01 | $30.01M 10-Q · filed 2015-11-03 | $36.76M derived: sum of 4 quarters · filed 2017-02-24 | ||
| 2015-06-30 | $14.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $22.02M 10-Q · filed 2016-08-01 | $22.02M 10-Q · filed 2015-08-04 | $28.77M derived: sum of 3 quarters · filed 2017-02-24 | |||
| 2015-03-31 | $7.25M 10-Q · filed 2016-05-03 | $14.00M derived: sum of 2 quarters · filed 2017-02-24 | |||||
| 2014-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $26.75M 10-K · filed 2017-02-24 | |||||
| 2014-09-30 | $20.00M 10-Q · filed 2015-11-03 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |